Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
We maintain our fair value estimate for TSMC stock.
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Trying to make sense of a share caught up in irrational exuberance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,291.79 | 29.09 | 0.35% |
| DAX 40 | 24,270.78 | 116.31 | 0.48% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,552.08 | 37.91 | -0.36% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |